[{"arm_notes": "", "treatment_id": null, "treatment_name": "Approximately 40 participants will be randomized in a 6:2 ratio. Arm 1 (n=approximately 30) will receive AZD7442.Arm 2 (n=approximately 10) will receive saline placebo.Cohort1: IM_ AZD 7442 300mg ; Cohort2 IM_AZD7442600mg ; Cohort3 IV_ AZD7442 300mg ; Cohort4_IV AZD7442 1000mg", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1465, "treatment_name": "Cilgavimab+tixagevimab", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Approximately 32 participants will be randomized in a 6:2 ratio. Arm 1 (n=approximately 24) will receive AZD7442.Arm 2 (n=approximately 8) will receive saline placebo.Cohort1: IM_ AZD 7442 300mg ; Cohort2 IM_AZD7442600mg ; Cohort3 IV_ AZD7442 300mg ; Cohort4_IV AZD7442 1000mg", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]